These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


132 related items for PubMed ID: 7229900

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Study of tablets. 10. Influence of non-ionic surfactants on the compressibility of sulfanilamide].
    DuchĂȘne D, Terrier JL, Clerc J, Puisieux F.
    Ann Pharm Fr; 1973; 31(9):583-92. PubMed ID: 4793701
    [No Abstract] [Full Text] [Related]

  • 4. [Influence of formation of an hydrophilic and continuous network of starch on tablets properties. II. Repercussion on tablets characteristics, depending on conditions of the compression (author's transl)].
    Ringard J, Guyot-Hermann AM.
    J Pharm Belg; 1979; 34(3):175-82. PubMed ID: 480129
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Contribution to the study on phenylbutazone-sulfamides. I. -- Phenylbutazone-sulfanilamide and phenylbutazone-sulfathiazol associations (author's transl)].
    Jeanjean B, Alberola S, Rambaud J, Sabon F.
    Ann Pharm Fr; 1979; 37(5-6):175-80. PubMed ID: 543592
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Study of tablets. 3. Influence of non-ionic surfactants with ester linkage on qualities of sulfanilamide grains and tablets].
    DuchĂȘne D, Djiane A, Puisieux F.
    Ann Pharm Fr; 1970 Apr; 28(4):289-98. PubMed ID: 5430303
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Phase transformation considerations during process development and manufacture of solid oral dosage forms.
    Zhang GG, Law D, Schmitt EA, Qiu Y.
    Adv Drug Deliv Rev; 2004 Feb 23; 56(3):371-90. PubMed ID: 14962587
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 7.